DENVER, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine" or the "Company") is pleased to announce that its subsidiary Mindleap Health (“Mindleap”), a digital health platform and the world's-first telemedicine application purpose-built for the psychedelic medicine industry, has filed a provisional patent for its technology platform in both The United States Patent and Trademark Office (USPTO) and the Canadian Intellectual Property Office.
“As our company continues to innovate we are focused on vigorous protection of all of our inventions,” said Mydecine CEO and Chairman Josh Bartch. “Mindleap’s software patents will strengthen our intellectual property portfolio overall which now totals 8 patent filings currently in process.”
Mindleap’s telemedicine platform combines mood, emotion and habit tracking that allows users to purchase and receive virtual mental health coaching from an international network of specialists. In the coming months, Mindleap’s software development team will introduce more advanced mental health and wellbeing tools including expert on-demand programs, streaming mental wellbeing content and convenient and affordable access to mental health support right from the palm of their hand. These inventions cover various advanced technologies currently in development with the most vital being digital mental health and wellbeing programs, enhanced data collection and aggregation, proprietary wellbeing score and personalized automated alerts and suggestions.
Since the launch of the initial app in Fall 2020, Mydecine has developed Mindleap 2.0, a refined version of the platform that enhances the end-user experience in order to deliver improved patient outcomes. Enhancements to the platform include improved remote telemedicine services and a newly reskinned user interface expected to launch in Spring 2021.
"We’re really excited about what we're working on right now at Mindleap. There are a number of advancements that we'll be introducing to the public over the next few months, and we can't wait to see how our users respond,” said Jack Bunce, Head of Digital at Mindleap. “More than ever before people are looking for ways to access high-quality, on-demand content that will positively impact their mental health and well-being. Through the creative partnerships we’ve formed and the digital programs we’ve developed, there is an outstanding opportunity to continue to leverage the telehealth experience into something that can help people make significant progress on their mental health journey."
Included in the launch of Mindleap 2.0 is the release of new Digital Mental Health and Well-Being Programs. Each of these new programs will feature daily audio and or video sessions created by world-class experts in each of their respective fields. The updated platform will also include various audio programs ranging from psychedelic integration, addiction, meditation, breathwork, cognitive behavioral therapy and others. As development progresses further, Mindleap technologies will include advancements that will take advantage of enhanced data collection and analytics to bring forth further assistance to users including a proprietary Mindleap Well-Being Score.
About Mindleap Health
Mindleap Health Inc. is a virtual healthcare company that offers technology solutions that allow people to improve their mental health and wellbeing. The Mindleap platform provides remote telemedicine services for mental health coaching through its international network of mental health specialists along with mental health tracking and analytics. The Mindleap platform brings convenience, improves access to treatments and can lead to more personal breakthroughs. Mindleap’s proprietary platform is designed to provide professional support and personalized treatment for every user. The company’s mission is to upgrade mental health by simplifying, modernizing, and improving access to mental health treatments for millions of people around the world.
On behalf of the Board of Directors:
Joshua Bartch, Chief Executive Officer
Charles Lee, Investor Relations
Mindleap Health Platform Services Disclaimer: Mindleap Services are designed to connect users of our Services with mental health specialists so as to receive assistance and guidance with integrating their prior psychedelic or consciousness-expanding experiences and translating them into positive changes. Our Services are not designed or intended for the integration or translation of a presently occurring psychedelic experience and must not be used for that purpose. Psychedelic substances are legally controlled or prohibited in many jurisdictions, but there are legal means to have a psychedelic or conscious-expanding experience in certain circumstances. You are solely responsible and liable for adequately informing yourself of the Laws of your jurisdiction before using our Services and determining if use of our Services and the receipt of Specialist Services (defined below) is lawful in your jurisdiction. Our Services are meant to be used exclusively in connection with lawful activities and must not be used in connection with illegal substances or illegal activities. Without limiting the previous sentence, you are not permitted to promote, procure, consume, or sell illegal substances through the Services. Do not use psychedelic substances if doing so is unlawful in your jurisdiction. Possession of psychedelic substances in violation of applicable laws can carry significant penalties, including years of incarceration.
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof. This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company's ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company's products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. This news release does not constitute an offer of securities for sale in the United States. These securities have not and will not be registered under United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to a U.S. Person unless so registered, or an exemption from registration is relied upon.